Volume 69, Issue 2, Pages (February 2016)

Slides:

Advertisements

Similar presentations

Volume 50, Issue 3, Pages (September 2006)

Advertisements

The PSA Era is not Over for Prostate Cancer

Volume 59, Issue 2, Pages (February 2011)

Urinary Nerve Growth Factor Levels are Elevated in Patients with Detrusor Overactivity and Decreased in Responders to Detrusor Botulinum Toxin-A Injection

A System for Long-term Urodynamic Studies Without Catheters

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

1Bristol Urological Institute 2Astellas Pharma Europe B.V.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Volume 50, Issue 5, Pages (November 2006)

Volume 71, Issue 4, Pages (April 2017)

Volume 50, Issue 6, Pages (December 2006)

Volume 53, Issue 5, Pages (May 2008)

Louis Spencer Krane, Mahendra Bhandari, James O. Peabody, Mani Menon

Let the Games Begin (with EAU Approval)

Prostate Cancer Epidemic in Sight?

Volume 45, Issue 4, Pages (April 2004)

Volume 64, Issue 4, Pages (October 2013)

Daily Administration of Phosphodiesterase Type 5 Inhibitors for Urological and Nonurological Indications Anthony J. Bella, Ling X. DeYoung, Mussa al-Numi,

Volume 64, Issue 4, Pages (October 2013)

The Global Risk of Bladder Cancer: Let's Just Do Something About It!

Volume 63, Issue 1, Pages (January 2013)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey John B. McKinlay, Carol L. Link European.

Volume 62, Issue 3, Pages (September 2012)

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Volume 70, Issue 3, Pages (September 2016)

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

Prostate Cancer Detection: A View of the Future

Volume 51, Issue 2, Pages (February 2007)

Volume 71, Issue 3, Pages (March 2017)

P.M.J. Moonen, L.A.L.M. Kiemeney, J.A. Witjes European Urology

Multipathogenetic Origin of a Pelvic Mass

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 63, Issue 5, Pages (May 2013)

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Volume 60, Issue 1, Pages (July 2011)

Volume 56, Issue 1, Pages (July 2009)

Treatment of Symptomatic Benign Prostatic Hyperplasia: Current and Future Clinical Practice in Europe – What is Really Happening? Bob Djavan European.

Volume 64, Issue 3, Pages (September 2013)

Volume 72, Issue 3, Pages (September 2017)

Volume 57, Issue 4, Pages e41-e42 (April 2010)

Volume 52, Issue 4, Pages (October 2007)

Volume 49, Issue 6, Pages (June 2006)

Prostate Cancer Epidemic in Sight?

Volume 48, Issue 4, Pages (October 2005)

The PSA Era is not Over for Prostate Cancer

Volume 61, Issue 5, Pages (May 2012)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Classification of Male Lower Urinary Tract Symptoms Using Mathematical Modelling and a Regression Tree Algorithm of Noninvasive Near-Infrared Spectroscopy.

Volume 54, Issue 2, Pages (August 2008)

The Economic Costs of Overactive Bladder in Germany

Volume 50, Issue 5, Pages (November 2006)

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Volume 74, Issue 5, Pages (November 2018)

Testicular Cancer Variations in Time and Space in Europe

Volume 54, Issue 6, Pages (December 2008)

Prognostic Impact of Comorbidity in Patients with Bladder Cancer

European Urology is “Your” Journal

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Volume 55, Issue 3, Pages (March 2009)

Economic Burden of Bladder Cancer Across the European Union

Volume 52, Issue 6, Pages (December 2007)

Volume 53, Issue 2, Pages (February 2008)

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Ian W. Mills, Anna Crossland, Anup Patel, Henrikas Ramonas

Volume 4, Issue 1, Pages 2-3 (February 2006)

Volume 54, Issue 1, Pages (July 2008)

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 69, Issue 2, Pages 361-369 (February 2016) Signs and Symptoms of Detrusor Underactivity: An Analysis of Clinical Presentation and Urodynamic Tests From a Large Group of Patients Undergoing Pressure Flow Studies Andrew Gammie, Mathilde Kaper, Caroline Dorrepaal, Ton Kos, Paul Abrams European Urology Volume 69, Issue 2, Pages 361-369 (February 2016) DOI: 10.1016/j.eururo.2015.08.014 Copyright © 2015 European Association of Urology Terms and Conditions

Fig. 1 Selection process of patients with detrusor underactivity, bladder outlet obstruction, and normal pressure flow studies tests using criteria in Table 1. BOO=bladder outlet obstruction; DO=detrusor overactivity, DU=detrusor underactivity; PFS=pressure flow studies. European Urology 2016 69, 361-369DOI: (10.1016/j.eururo.2015.08.014) Copyright © 2015 European Association of Urology Terms and Conditions